NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo.

Saved in:
Bibliographic Details
Title: NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo.
Authors: Namoto K; Biomedical Research, Novartis Pharma AG, Basel, Switzerland. Electronic address: kenji.namoto@novartis.com., Baader C; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland; University of Basel, Basel, Switzerland., Orsini V; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Landshammer A; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Breuer E; University Hospital Zurich (USZ), Zurich, Switzerland., Dinh KT; German Cancer Research Center (DKFZ) Heidelberg, Research Group Experimental Hepatology, Inflammation and Cancer, Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Ungricht R; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Pikiolek M; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Laurent S; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Lu B; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA., Aebi A; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Schönberger K; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Vangrevelinghe E; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Evrova O; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Sun T; Biomedical Research, Novartis Pharma AG, Basel, Switzerland; Division of Liver Diseases, Institute for Regenerative Medicine, Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Annunziato S; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Lachal J; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Redmond E; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA., Wang L; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA., Wetzel K; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA., Capodieci P; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA., Turner J; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Schutzius G; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Unterreiner V; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Trunzer M; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Buschmann N; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Behnke D; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Machauer R; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Scheufler C; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Parker CN; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Ferro M; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Grevot A; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Beyerbach A; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Lu WY; University of Edinburgh, Center for Inflammation Research, Edinburgh, UK., Forbes SJ; University of Edinburgh, Center for Regenerative Medicine, Edinburgh, UK., Wagner J; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Bouwmeester T; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Liu J; Biomedical Research, Novartis Pharma AG, La Jolla, CA, USA., Sohal B; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Sahambi S; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA., Greenbaum LE; Biomedical Research, Novartis Pharma AG, East Hanover, NJ, USA., Lohmann F; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Hoppe P; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Cong F; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA., Sailer AW; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Ruffner H; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Glatthar R; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Humar B; University Hospital Zurich (USZ), Zurich, Switzerland., Clavien PA; University Hospital Zurich (USZ), Zurich, Switzerland., Dill MT; German Cancer Research Center (DKFZ) Heidelberg, Research Group Experimental Hepatology, Inflammation and Cancer, Heidelberg, Germany; Department of Gastroenterology, Infectious Diseases and Intoxication, Heidelberg University Hospital, Heidelberg, Germany., George E; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA., Maibaum J; Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Liberali P; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland; University of Basel, Basel, Switzerland., Tchorz JS; Biomedical Research, Novartis Pharma AG, Basel, Switzerland. Electronic address: jan.tchorz@novartis.com.
Source: Cell stem cell [Cell Stem Cell] 2024 Apr 04; Vol. 31 (4), pp. 554-569.e17.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101311472 Publication Model: Print Cited Medium: Internet ISSN: 1875-9777 (Electronic) Linking ISSN: 18759777 NLM ISO Abbreviation: Cell Stem Cell Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1875-9777
DOI:10.1016/j.stem.2024.03.003